Results 51 to 60 of about 38,997 (290)

Active surveillance of drug safety in healthcare data: Sequential monitoring of bacterial and serious urinary tract infection risk in sodium‐glucose cotransporter 2 inhibitor users

British Journal of Clinical Pharmacology, EarlyView.
Abstract Introduction Active surveillance of adverse events using healthcare data is emerging as complementary to the monitoring of spontaneous reports and stand‐alone pharmacoepidemiologic studies. The risk of urinary tract infections (UTIs) was listed as a special warning for sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) when marketed in Europe
Haoxin Le, Dilsad Simay Peker, Lukas Frederic Westphal, Nikolai Brun, Christine Erikstrup Hallgreen, Morten Andersen   +5 more
wiley   +1 more source

Glimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxide [PDF]

, 2001
Background: The sulfonylurea glibenclamide (Glib) abolishes the cardioprotective effect of ischemic preconditioning (IP), presumably by inhibiting mitochondrial KATP channel opening in myocytes. Glimepiride (Glim) is a new sulfonylurea reported to affect
Baxter, G.F., Lawrence, C.L., Maddock, H.L., Mocanu, M.M., Standen, N.B., Yellon, D.M.   +5 more
core  

Comparative effectiveness of dipeptidyl peptidase-4 (DPP-4) inhibitors and human glucagon-like peptide-1 (GLP-1) analogue as add-on therapies to sulphonylurea among diabetes patients in the Asia-Pacific region: a systematic review [PDF]

, 2014
The prevalence of diabetes mellitus is rising globally, and it induces a substantial public health burden to the healthcare systems. Its optimal control is one of the most significant challenges faced by physicians and policy-makers.
A Juutilainen, AA Riedel, AI Adler, AJ Garber, AR Saltiel, BD Green, BI Yan, BM Scirica, Brian C. Y. Fong, C Castell, C Levetan, Carmen K. M. Fan, CC Cowie, CE Van Dijk, CJ Bailey, CN Chan, Daisy D. X. Zhang, DC Simonson, DR Owens, DS Schade, FA Guisasola, François Blachier, Harry H. X. Wang, J Lopatynski, J Mest H, J Rosenstock, K Kaku, Kirin Q. L. Liu, L Groop, M Kobayashi, M Stumvoll, M Takihata, Mandy W. M. Kwan, Martin C. S. Wong, MC Wong, N Inagaki, N Inagaki, O Mosenzon, R Kawamori, RA DeFronzo, S Aronoff, S Clement, SE Kahn, SE Kahn, SE Nissen, Shannon T. S. Li, Sian M. Griffiths, Sky W. M. Chan, SL Zhang, T Kadowaki, V Mohan, W Gareth, W Yang, WB White, Y Guan, Y Seino, Y Seino, YG Kim, Z Zeng   +58 more
core   +3 more sources

Cardiorenal Outcomes of Dapagliflozin vs. Empagliflozin in Advanced Chronic Kidney Disease and Diabetes

Clinical Pharmacology &Therapeutics, EarlyView.
Target trial emulation of a multi‐institutional electronic health record network showed comparable cardiorenal effectiveness and safety of dapagliflozin versus empagliflozin in adults with type 2 diabetes and advanced‐stage chronic kidney disease.
Shih‐Hsuan Lin, Jia‐Jin Chen, Ching‐Chung Hsiao, Yu‐Wei Fang, Meng‐Ting Chen, Ming‐Hsien Tsai, Huang‐Yu Yang   +6 more
wiley   +1 more source

Cryo-EM structure of the ATP-sensitive potassium channel illuminates mechanisms of assembly and gating

eLife, 2017
KATP channels are metabolic sensors that couple cell energetics to membrane excitability. In pancreatic β-cells, channels formed by SUR1 and Kir6.2 regulate insulin secretion and are the targets of antidiabetic sulfonylureas.
Gregory M Martin, Craig Yoshioka, Emily A Rex, Jonathan F Fay, Qing Xie, Matthew R Whorton, James Z Chen, Show-Ling Shyng   +7 more
doaj   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Resistência de plantas daninhas aos herbicidas inibidores da ALS na cultura da soja (Glycine max) Weed resistance to ALS - inhibiting herbicides in soybean (Glycine max) crop

Planta Daninha, 2000
As plantas daninhas Bidens pilosa/Bidens subalternans (picão-preto) e Amaranthus quitensis (caruru) são controladas na cultura da soja por diversos herbicidas, sendo os inibidores da acetolactato sintase (ALS) os mais utilizados pelos sojicultores. O uso
P.A. Monqueiro, P.J. Christoffoleti, C.T.S. Dias   +2 more
doaj   +1 more source

Reasoned Opinion on the review of the existing maximum residue levels (MRLs) for amidosulfuron according to Article 12 of Regulation (EC) No 396/2005 [PDF]

EFSA Journal, 2014
According to Article 12 of Regulation (EC) No 396/2005, the European Food Safety Authority (EFSA) has reviewed the Maximum Residue Levels (MRLs) currently established at European level for the pesticide active substance amidosulfuron.
European Food Safety Authority
doaj   +1 more source

Turfgrass species response exposed to increasing rates of glyphosate application [PDF]

, 2009
To investigate the response of nine turfgrass species exposed to increasing rates of glyphosate application, the dry matter production, visual leaf injury symptoms (e.g., chlorosis and necrosis) and the concentrations of shikimate and mineral nutrients ...
Budak, Hikmet, Cakmak, Ismail, Ozturk, Levent, Su, Y. Senem, Çakmak, İsmail, Öztürk, Levent   +5 more
core   +1 more source

Sodium‐glucose cotransporter 2 inhibitors and the risk of late onset epilepsy: A real‐world cohort study

Epilepsia, EarlyView.
Abstract Objective Late onset epilepsy (LOE) is associated with substantial morbidity. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) may exert neuroprotective effects. This study evaluated the association between SGLT2i and risk of LOE among older adults with type 2 diabetes mellitus.
Bing‐Hua Lin, Hui‐Min Huang, Hui‐An Lin, Sheng‐Feng Lin   +3 more
wiley   +1 more source